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Gingipains are the major virulence factors of Porphyromonas gingivalis, the main periodontopathogen. It is
expected that inhibition of gingipain activity in vivo could prevent or slow down the progression of adult
periodontitis. To date, several classes of gingipain inhibitors have been recognized. These include gingipain
N-terminal prodomains, synthetic compounds, inhibitors from natural sources, antibiotics, antiseptics,
antibodies, and bacteria. Several synthetic compounds are potent gingipain inhibitors but inhibit a broad
spectrum of host proteases and have undesirable side effects. Synthetic compounds with high specificity for
gingipains have unknown toxicity effects, making natural inhibitors more promising as therapeutic gingipain
blockers. Cranberry and rice extracts interfere with gingipain activity and prevent the growth and biofilm
formation of periodontopathogens. Although the ideal gingipain inhibitor has yet to be discovered, gingipain
inhibition represents a novel approach to treat and prevent periodontitis. Gingipain inhibitors may also help
treat systemic disorders that are associated with periodontitis, including cardiovascular disease, rheumatoid
arthritis, aspiration pneumonia, pre-term birth, and low birth weight.
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P
eriodontitis is a set of inflammatory diseases affect-
ing the periodontium, that is, the tissues surround-
ing and supporting the teeth. It causes loss of the
alveolar bone around the teeth, and if left untreated, can
cause loosening and subsequent loss of teeth. Micro-
organisms that adhere to and grow on the tooth’s surfaces
(dental plaque), together with an over-aggressive immune
response against them, are generally believed to be the
causes of periodontitis. There are seven major catego-
ries of periodontitis (1), of which chronic periodontitis
and aggressive periodontitis are of particular impor-
tance for human health. Periodontitis is a mixed infection
where particularly the red complex of bacteria, consisting
of Porphyromonas gingivalis, Tannerella forsythia, and
Treponema denticola, is clinically important (2).
Gingipains are the primary virulence factors of P.
gingivalis. The direct and indirect activities of gingipains
areimportant in every stage of infection, including attach-
ment andcolonization, acquisition of nutrients, evasion of
host defense, and tissue invasion and dissemination (3).
Gingipainsarebacterialhouse-keepingenzymes;theyplay
a key role in the pathogenic functions of P. gingivalis, such
as fimbriae assembly and processing of outer membrane
proteins. Gingipains also digest a broad spectrum of host
proteins. Some of these are completely degraded, which
furnishespeptidesforP.gingivalisgrowthandmetabolism,
while others are subjected to a limited or selective pro-
teolysis, which leads to the dysregulation of host defen-
sive inflammatory reactions and failure to eliminate P.
gingivalis.
The gingipain family comprises three related cysteine
proteases that hydrolyze peptide bonds at the carbonyl
groups of arginine (Arg-Xaa) and lysine residues (Lys-
Xaa).Thehomologousarginine-specificgingipains,RgpA
and RgpB, are products of two related genes rgpA and
rgpB, whereas the Lys-specific gingipain, Lys-gingipain
(Kgp), is encoded by the kgp gene (4). RgpB is exported
into the periplasm as a proprotein composed of an
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C-terminal domain (CTD). By contrast to RgpB, RgpA
and Kgp have a large hemagglutinin/adhesion domain
(HA domain) inserted between the protease and CTD
domains. In the periplasm, or during translocation across
the outer membrane, progingipains undergo extensive
proteolytic processing. NPD and CTD are cleaved off
whiletheHAdomaininRgpAandKgpisfragmentedinto
subdomains. These subdomains arebound to the protease
domain via non-covalent interactions (5). Mature gingi-
painsareeithersecretedinthesolubleform,oradditionally
glycosylated with anionic LPS, which allows them to
remain associated with the outer membrane. On the bac-
terial membrane surface RgpA and Kgp form large multi-
domain, multifunctional complexes that engage in proteo-
lysis, hem acquisition, platelet activation, red blood cell
agglutination,hemolysis,andadhesiontotheextracellular
matrix. This multi-functionality of gingipains accounts
for the severely decreased virulence of gingipain knock-
out strains in animal models of bacterial infection, in-
cluding periodontitis, and immunization with gingipains
provides protection from P. gingivalis inoculation-induced
pathological changes in vivo. These studies indicate that
gingipains are promising targets for the development
of inhibitors that could be used for the treatment of
periodontitis.
To develop successful therapeutic gingipain inhibitors,
the gingipain chiefly responsible for the virulence of P.
gingivalis must be clearly identified. Reynolds et al.
initially implicated Kgp, and then RgpB, as the primary
virulence factor of P. gingivalis in a murine model of
alveolar bone loss (6). However, recent findings have as-
signed this role to RgpA (7). Regardless of this discre-
pancy, it is clear that the gingipains are indispensable
for P. gingivalis virulence and optimally both Kgp and
Rgp activity should be targeted for the treatment
and/or prevention of periodontitis. An ideal therapeutic
compound should also block the proteolytic activity-
independent functions of RgpA and Kgp, which have
also been implicated in P. gingivalis pathogenicity,
although blocking all of the virulence-supporting func-
tions is a challenging and difficult task. Recent develop-
ments in the understanding of the mechanism of gingipain
processing and secretion have identified these processes
as therapeutic targets. Targeting processing and secre-
tion would remove all ofthevirulence-associated activities
of gingipains. Yongqing at al. recently reviewed poten-
tial strategies for the inhibition of P. gingivalis Kgp (8)
and Grenier and La (9) published a review on proteases
in P. gingivalis as potential targets for plant-derived
compounds. The aim of this current review is to provide
an up-to-date account of research into the different
approaches that have been used to inhibit gingipain
activity (Table 1).
Possible biological effects of administration of
gingipain inhibitors
The possible effects of administration of gingipains
inhibitors need be studied in vitro and in vivo. A likely ef-
fect of inhibitors administration in vivo may result in a
reduction in the level of colonization by P. gingivalis. The
proteolytic activity of this bacterium is not only disease-
related but is there to provide nutrients. Therefore,
suppression of proteolytic activity may also reduce
concentrations of peptide substrates and micro-nutrients
for P. gingivalis. This can be shown in vitro by analysis of
gingipain mutants. Furthermore, the loss of proteolytic
activity is likely to render the bacterium more susceptible
to the normal bacterial clearance operating in the peri-
odontal tissues. Finally, it is possible that inhibition of
the hemagglutinin domains may influence the ability of
P. gingivalis to adhere to and colonize the tooth surface/
periodontal pocket.
Gingipain inhibition via targeting of the NPD
The most common way to spatially and/or temporally
control protease activity in vivo is through synthesis of
proteases in zymogenic forms. Zymogenicity is often
exerted by an NPD. This strategy is employed by P.
gingivalis to maintain gingipains enzymatically inert until
they are secreted outside the cell. The NPDs of gingipains
arecomposed of about 200 amino acidresiduesfolded in a
well-structured domain. NPDs from Rgps expressed in
Table 1. List of gingipain inhibitors with references
N-terminal prodomain (NPD) (913)
Proteinaceous protease inhibitors (1420)
Viruses (21)
Rice-derived inhibitors (22, 23)
Proteins, peptides, and protein-derived peptides:
Lactoferrin (24)
Histatin (25)
k-casein (26)
Cyanate hydratase-derived peptide (22)
Peptide analogues:
Aza-peptide Michael acceptors (27)
A7156 (28)
KYT inhibitors (29)
DX-9065a (30, 31)
Chloromethane and chloromethyl ketones (32, 33)
FA-70C1 (34)
Antibiotics and antiseptics (3542)
Sword bean extract (SBE) and canavanine (43, 44)
Cranberry-derived polyphenols (4649)
Green tea-derived polyphenols (5059)
Myrothamnus flabellifolia-extract (60)
IgY and vaccines (42, 6181)
Other bacteria (82)
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trans with a Ki in the low nanomolar range (10, 11). In the
inhibitory complex, the NPD is attached laterally to the
catalytic domain through a large concave surface (Fig. 1).
Inhibition is maintained by a surface ‘inhibitory loop’,
which approaches the active-site cleft of the enzyme on its
non-primedsideinasubstrate-likemanner,resultinginthe
insertion of Arg-126 into the S1 pocket (12). The NPD
inhibitory loop matches the enzyme-substrate specificity
(13).DownstreamofArg-126,thepolypeptidechainofthe
NPD leaves the cleft, thus avoiding proteolysis. The
proteolytic activity of RgpB is also compromised by a
strong hydrogen bond betweenthe carbonyl group of Arg-
126 in the NPD and the co-catalytic histidine. The
hydrogen bond pulls the catalytic histidine residue away
from the catalytic cysteine, Cys-473 (12). This structural
knowledge should facilitate the development of novel
RgpB inhibitors and zymogenic inhibitors for other
peptidases.
The high-affinity inhibitory interaction between the
NPD and the catalytic domain of Rgp suggests that the
prodomain must be degraded to release the active,
proteolytic form of Rgp during enzyme maturation and
secretion The NPD of Kgp has negligible inhibitory
activity in trans. Nevertheless, it is likely that it still
maintains proKgp inactive when in cis. It is important
to emphasize that recombinant NPDs efficiently inhibit
the activity of Rgps in whole P. gingivalis cells for
prolonged periods of time. Therefore, the therapeutic
application of NPDs, formulated to penetrate periodontal
pockets, may attenuate P. gingivalis virulence and prevent
the development of periodontitis.
Gingipain inhibition by proteinaceous protease
inhibitors
Mammalian inhibitors of gingipains
Proteinase inhibitors constitute 10% of the protein con-
tent of human plasma and are also found in tissue fluids.
However, gingipain activity is affected only by a handful
of these natural proteolysis regulators. The trypsin-like
activity of P. gingivalis, attributed to its Rgp proteases,
is inhibited by antithrombin III (ATIII) (Kass5.6510
4
M
1 s
1) in a reaction enhanced by heparin (14). RgpA
and RgpB, but not Kgp, are inhibited by human alpha-
2-macroglobulin (a2M). A homologous macroglobulin
from rat plasma, alpha-1-inhibitor 3, blocked the activ-
ity of all three gingipains (15). Conversely, the major
cysteine protease inhibitors, the cystatins, have little
effect on gingipain activity (16). Nevertheless, chicken
cystatin, cystatin C, and cystatin S inhibited the growth
of P. gingivalis in culture (17, 18). Low molecular mass
inhibitors of Rgps had no effect on P. gingivalis growth,
indicating that the antibacterial activity of cystatins is not
dependent on Rgp inhibition.
Pancreatic secretory Kazal-type trypsin inhibitors are
another type of mammalian proteinase inhibitors that
block gingipain activity. The porcine Kazal-type trypsin
inhibitor, which possesses a Lys residue at the P1 position,
exclusively inhibited Kgp, whereas a bovine inhibitor,
which possesses an Arg residue at the P1 position,
specifically blocked the activity of the Rgps (19). Kazal-
typetrypsininhibitorsarenotexpressedinhumangingival
and periodontal tissues, but human homologues of these
inhibitors could be used asatherapytotreat periodontitis.
Virus gingipain inhibitors
Among virally encoded caspase inhibitors, the cowpox
virus cytokine-response modifier A (CrmA) serpin and a
baculovirus p35 inhibitorof apoptosis inhibit Kgp but not
Rgp (20). To achieve Kgp inhibition, CrmAwas modified
by replacing the P1 Asp residue with a Lys residue at the
reactive site. By contrast to CrmA, Kgp was efficiently
inhibited by wild-type p35. Gingipains and caspases are
members of the CD clan of proteases and share a similar
3D fold (21). Therefore, gingipain inhibition indicates that
virally encoded caspases have adopted a mechanism that
allows them to regulate disparate members of the clan CD
protease family.
Rice-derived inhibitors
Plant fruits and seeds are rich in proteinaceous protease
inhibitors. To date, plant-derived proteins capable of
inhibiting gingipains have only been characterized in rice
(Oryza sativa). The rice grain extract exhibited high levels
of gingipain inhibitory activity towards both Kgp and
Rgps. The inhibitory activity was highly diverse with
respect to molecular mass and isoelectric point. Four
proteins, namely the 26-kDa Globulin (NCBI database
accession number: 115464709), a plant lipid transfer/
trypsin and a-amylase inhibitor (accession # 115471167),
an RA17 seed allergen (accession # 115471171), and
an a-amylase inhibitor/trypsin inhibitor (accession #
115471201), are the main components responsible for
Rgp inhibitory activity in rice extract (22), and are largely
responsible for the suppression of gingipain-dependent P.
gingivalis virulence and bacterial growth in media with
transferrin as an iron source (23). The presence of an Arg
residue in the loop of two of the rice gingipain inhibitors,
a-amylase inhibitor/trypsin inhibitor and an RA17 seed
allergen, correlates with their ability to inhibit Rgps.
Other rice proteins that interact with Rgps are anno-
tated in the MEROPS peptidase database (http://merops.
sanger.ac.uk/cgi-bin/famsum?familyI6) and are denoted
as a family of 16 unassigned peptidase inhibitor homo-
logues. They share significant primary structure, including
10 conservative cysteine residues, with an archetypical
inhibitor of the I6 family, the ragi seed trypsin/alpha-
amylase inhibitor from Eleusine coracana (MEROPS
Accession MER018247) (Fig. 2a). This implies conserva-
tionofthetertiarystructure,includinganexposedreactive
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(page number not for citation purpose)Fig. 1. The structure of the zymogenic complex of the N-terminal prodomain (NPD) with mature RgpB. (a) Ribbon-type plot in
wall-eyed stereo image of the complex between the RgpB PD (in blue/magenta) and the mature RgpB moiety in front view. The
latterconsistsofdomainsCD(inyellow/orange)andIgSF(ingreen/brown).Thethreecalciumionsandthebariumionsaredepic-
tedasredandmagentaspheres,respectively.TheinhibitoryloopandtherespectiveNandCterminiarelabeled,inturquoiseforPD
andinbrownforCDIgSF.Arg
126fromthePDinhibitoryloopandtheactive-siteresiduesofCD(Cys
473,His
440,andGlu
381)are
furthershownassticksforreferenceoftheactivesite.(b)OrthogonalviewofashowingtheCDinstandardorientation,thatis,with
theviewintotheactive-sitecleft,whichrunshorizontallyfromleft(non-primedside)toright(primedside).(c)Viewofthecomplex
in the orientations of a (left) and b (right) showing the regions of the PD and CD engaged in binding in dark blue and orange,
respectively.Therestofeachmoleculeisshowninturquoiseandyellow,respectively.(d)Close-upviewinwall-eyedstereoimageof
the area around the inhibitory loop delimited by a black rectangle in c. The CD moiety is shown as a tan ribbon, and selec-
tedresiduesarelabeledandshownfortheirsidechainsasstickswithtancarbons.Theinhibitoryloop(Lys
121Tyr
135)isshownasa
stickmodelwithcarbonsinturquoise.Selectedresiduesarealsolabeled.ThebariumionoftheCDisdepictedasamagentasphere.
Note that the catalyticcysteine, Cys
473, is oxidizedto 3-sulﬁno-L-alanine (residue name CSD). Obtained from deDiego et al. (12).
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Inhibitors belonging to the I6 family exclusively in-
hibit serine proteases. Therefore, gingipain inhibition by
rice I6 family members represents a novel type of
inhibitory interaction. I6 family proteins are abundant in
many cereal plants, including Sorghum bicolor, Zea mays
(maize), Triticum aestivum (wheat), Brachypodium dis-
tachyon, Hordeum vulgare (barley), Secale cerede (rye),
and Eleusine coracana (millet), and they may be capable
of gingipain inhibition. Systematic biochemical stu-
dies are needed to isolate such proteins and investigate
their enzyme kinetics and structural interactions with
gingipains. This could lead to the development of food
formula (nutraceuticals) that prevent the initiation and/or
progression of periodontitis.
Gingipain inhibition by proteins, peptides, and
protein-derived peptides
Lactoferrin
Lactoferrin, an 80-kDa-iron-binding glycoprotein pre-
sent in saliva and gingival crevicular fluid, inhibits
Fig. 2. Rice-derived proteins inhibiting gingipains. (a) Crystal structure-guided alignment of a bifunctional inhibitor of alpha-
amylase and trypsin (RATI) from ragi seeds (Indian ﬁnger millet, Eleusine coracana Gaertneri) (MER018247) and rice-derived
proteins inhibiting gingipains: alpha-amylase/trypsin inhibitor (MER029341), seed allergic protein RA17 precursor
(MER023398) and plant lipid transfer/seed storage/trypsin-alpha amylase inhibitor domain containing protein (MER023521).
Conserved cysteine residues and arrangement of disulﬁde bridges are highlighted yellow and induced by the identical digit
between the RATI and MER029341 sequences, respectively. Amino acid residues forming alpha-helixes (A, B, C, and D) are in
bold blue font and the reactive site loop is located between helixes A and B. The reactive site Arg residue in the RATI structure is
in the bold red font. Arg residues in rice proteins, which may be recognized by Rgps as the P1 residues in the inhibitory reaction
are highlighted turquoise. ‘-’ gaps introduced into sequences to facilitate the alignment using the ClustalW program (http://
embnet.vital-it.ch/software/ClustalW.html). (b) The crystal structure of RATI (PDB database: 1B1U). The reactive site residue
Arg34 is shown in ball-and-stick representation in purple.
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biofilm inhibitory activity even when incubated with P.
gingivalis (24). This activity is probably related, at least
in part, to its anti-protease effect. Lactoferrin is relatively
resistant to hydrolysis by P. gingivalis proteases and
may play an important role in preventing P. gingivalis-
associated diseases via innate immunity.
Histatin
Histatin 5 is a salivary peptide rich in His residues with
antifungal and antibacterial activity. It is not a typical
protease inhibitor; however, it inhibits both the host ma-
trix metalloproteases, MMP-2 and MMP-9, with IC50
values of 0.57 and 0.25 mM, respectively, and gingipains.
Kinetic analysis has revealed that histatin 5 is a compe-
titive inhibitorof Rgps, with a Ki of 15 mM. Histatin 5 also
inhibits Kgp but the mechanism of inhibition was not
determined (25). Since inhibition of both bacterial and
host proteases occurs at physiological concentrations,
histatin 5 could be an interesting candidate in clinical
trials directed toward finding a therapy for the treatment
and/or prevention of periodontitis.
k-casein
Bovine milk caseins are a rich natural source of peptides
withbiological activity. Toh et al. (26) identified a k-casein
(residues 109137) from a chymosin digest of casein, as
an inhibitory peptide of all P. gingivalis gingipains. The
synthesized peptide inhibited the proteolytic activity
associated with whole cells of P. gingivalis, purified
RgpA-Kgp adhesion complexes, and purified RgpB.
The k-casein acted synergistically with Zn (II) against
both Rgps and Kgp. Preincubation of P. gingivalis with
k-casein significantly reduced lesion development in a
murine infection model.
Cyanate hydratase-derived peptide
Anotherpeptidewithinhibitoryactivityagainstgingipains
is derived from cyanate hydratase, a rice extract protein.
A synthetic dodecapeptide (RRLMAAKAESRK) corre-
sponding to residues 3348 of cyanate hydratase inter-
fered with both Rgp and Kgp and inhibited bacterial
growth in a dose-dependent manner (22).
Gingipain inhibition by peptide analogs
Aza-peptide Michael acceptors
Ekici et al. (27) found that aza-peptide Michael acceptors
are highly potent and specific for the clan CD cysteine
protease family to which gingipains belong. Aza-Lys and
aza-Orn derivatives potently inhibited Kgp and clostri-
pain,andshowednocross-reactivitywithclanCAcysteine
proteases, such as papain, cathepsin B, and calpain.
Unfortunately, none of these inhibitors were tested for
their effect on P. gingivalis virulence.
A71561
A compound, 1-(3-phenylpropionyl)piperidine-3-(R,S)-
carboxylic acid-[4-amino-1(S)-(benzothiazole-2-carbonyl)
butyl] amide (A71561), is a specific, slowly reversible
inhibitor of Kgp with a Ki in the nanomolar range.
A71561 reduced the virulence of P. gingivalis in a murine
in vivo infection model if bacteriawere pre-incubatedwith
the compound before inoculation (28). However, to exert
this beneficial effect, wild-type P. gingivalis cells had
to be exposed to a high concentration (2 mM) of A71561,
despite complete Kgp inhibition in the inoculum at
concentrationsB0.1 mM.
KYT inhibitors
Small peptide analogs, such as carbobenzoxy-Lys-Arg-
CO-Lys-N-(CH3)2 (KYT-1) and carbobenzoxy-Glu
(NHN(CH3)Ph)-Lys-CO-NHCH2Ph (KYT-36), strongly
inhibit the degradation of human type 1 collagen,
immunoglobulins, fibronectin, fibrinogen, the disruption
of the bactericidal activity of polymorphonuclear leuko-
cytes, and increases in vascular permeability (29). KYT-1
and KYT-36 have low toxicity and are potent, subnano-
molar and selective inhibitors for Kgp and Rgp, respec-
tively. Recently KYT-41, a dual inhibitor of both types of
gingipains was developed (30). Evaluation of its biologi-
cal potency in vitro and in vivo revealed very good
selectivity for gingipains over host proteases, high in-
hibitory (Ki40 nM and 0.27 nM for Rgp and Kgp,
respectively) and ability to abrogate manifold pathologi-
cal functions of P. gingivalis. Importantly, the therapeutic
potential of KYT-41 was revealed by ability to suppress
the vascular permeability that was enhanced in guinea
pigs by P. gingivalis and the gingival inflammation in a
beagle dog periodontitis model. Therefore among all the
inhibitors already mentioned in this review, this makes
them the most suitable candidates for the treatment of
periodontitis.
DX-9065a
DX-9065a is a selective factor Xa (FXa) inhibitor that
blocks the protease activity of FXa in an anti-thrombin
III-independent manner (31). This compound was shown
to efficiently inhibit gingipains activity and suppress the
growth of P. gingivalis and Prevotella intermedia (32).
Chloromethane and chloromethyl ketones
Potempa et al. (33) found that chloromethane com-
pounds inhibit all three forms of gingipains to varying
degrees depending on the peptidyl component of the
inhibitor. Compounds containing a basic residue at P1
rapidly inactivated gingipains with some specificity being
conferred by the P2 site. Kgp was rapidly inhibited by the
(acyclo)methane inhibitor Cbz-Phe-Lys-CH2OCO-2,4,
6-Me3-Ph. This inhibitor and the peptidyl chloromethanes
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the most specific among those tested for Rgp inhibition.
Chloromethyl ketones have been used as model com-
pounds to study the specificity of the Sn binding region of
RgpB and Kgp and to reveal the structural preferences of
gingipains in this region (34). Among three series of
inhibitors with Arg or Lys at the P1 position and various
substitutionsatP2andP3,smallligands,suchasdipeptide
analogs, were found to display high potency (kobs/[1] 10
7
M
1 s
1) for gingipains. Unfortunately, chloromethyl
ketones are not suitable for in vivo studies because they
react with primary amino groups.
FA-70C1
FA-70C1 is an antipain analog composed of phenylalanyl-
ureido-citrullinyl-valinyl-cycloarginal isolated from the
culture supernatant of the Streptomyces species strain
FA-70 (35). FA-70C1 inhibits Rgps with a Ki of 4.5 nM
and human cathepsins B, L, and H with Ki values much
higher than those of Rgps. FA-70C1 dose-dependently
prevented the adverse effects of the P. gingivalis culture
supernatant on thebactericidal activityof neutrophils and
the viability of human fibroblasts and umbilical vein
endothelial cells. FA-70Cl blocked the enhancement of
vascular permeability induced by in vivo administra-
tion of the P. gingivalis culture supernatant. Additionally,
FA-70C1 dose-dependently suppressed the growth of
P. gingivalis. All these beneficial effects were exerted
despite the fact that FA-70C1 does not inhibit Kgp. This
suggests that Rgps should be the primary targets for the
development of inhibitor-based therapies, and FA-70C1
could be a useful tool for the prevention of P. gingivalis
virulence.
Gingipain inhibition by antibiotics and
antiseptics
Antibiotics can target bacterial proteases (36). Benzami-
dine derivatives inhibit the activity of RgpA and RgpB
(37, 38). Among these derivatives, bis-benzamidine, with a
urea linker, was the most potent for Rgp inhibition.
Application of low concentrations of zinc increased the
benzamide derivative inhibition of Rgps by two- to three-
fold. Benzamidine derivatives also bind to the P. gingivalis
chaperone, GroEL, as well as to Rgps, and it is unclear
which interaction is responsible for reduction of the
mortality rate in a fertilized egg model of P. gingivalis
pathogenicity (39).
Chlorhexidine, tetracyclines, and non-antimicrobial
chemically modified tetracycline derivatives have all
been reported to inhibit gingipains and inhibition was
increased by the addition of zinc (4042). Chlorhexidine,
cetylpyridium chloride, minocycline, and doxycycline
all partially inhibited the Rgp-induced degradation of
collagen-guided tissue regeneration membranes in P. gin-
givalis vesicles in solution, whereas metronidazole had no
such effect (43). Tetracyclines at 100 mM totally inhibited
the amidolytic activity of RgpA and RgpB. These effects
on gingipains may partially explain the therapeutic effect
of tetracyclines in periodontitis treatment.
Gingipain inhibition by sword bean extract and
canavanine
The fruit of the domesticated legume, Canavalia gladiate
(commonly referred to as sword bean), is used in Chinese
and Japanese herbal medicine for treating pus discharge.
ThefruitcontainsL-canavanine,inwhichtheN-methylene
of L-arginine is replaced by N-O. L-Canavanine inhibits
microbial arginine deiminases (ADIs); thus, it may be
the compound responsible for the pharmacological effect
of sword bean extract (SBE) (44). Recently, Nakatsuka
et al. (45) showed that SBE and canavanine inhibited
the growth of P. gingivalis and Fusobacterium nucleatem.
SBE also inhibited the activity of P. gingivalis cell-
associated Rgp with an efficacy comparable to that of
leupeptin. SBE inhibition of Kgp was weaker than that
of Rgp. Although canavanine has been implicated as
the compound responsible for gingipain inhibition, the
direct effect of pure canavanine on gingipain activity
has not been tested. However, oral administration of
SBE suspended in carboxyl methylcellulose completely
suppressed P. gingivalis-induced alveolar bone resorption
in a rat model of periodontitis. This therapeutic effect
of SBE is likely to be due to a combination of the direct
antimicrobial action of canavanine and canavanine inhibi-
tion of gingipains. It is important to note that canavanine
can also inhibit two other P. gingivalis enzymes; namely,
extracellular peptidyl arginine deiminase (PPAD) and
cytoplasmic ADI (46).
SBE and canavanine have lower cytotoxicity than
chlorhexidine gluconate (45), a product already used as
an active substance in wound dressings and antiseptic
mouthwashes, and as a preservative in eye drops. This
reduces safety concerns for SBE and would facilitate
the testing of SBE in human clinical trials as an ad-
junct therapy for the routine mechanical treatment of
periodontitis.
Gingipain inhibition by cranberry-derived
polyphenols
Proteases of periodontopathogens (P. gingivalis, T.
forsythia, and T. denticola) were efficiently inhibited by a
high-molecular-weight fraction isolated from cranberry
juice concentrate as non-dialyzable material (NDM).
NDM containing polyphenols (65% proanthocyanidins)
also prevented degradation of type 1 collagen and trans-
ferrin by whole P. gingivalis cells (47). Inhibition of Rgp
and Kgp activity by the polyphenol fraction of cranberry
was confirmed in an independent study, which showed
that this fraction also significantly inhibited synergistic
biofilm formation by P. gingivalis and F. nucleatum.
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pain activity occurred at an NDM concentration of ap-
proximately 1 mg/mL (48). Cranberry-derived proantho-
cyanidins neutralized all the virulence properties of P.
gingivalis but did not interfere with bacterial growth.
NDM reduced activation of the NF-kB p65 proinflam-
matory pathway (49), inhibited the adhesion of P.
gingivalis and F. nucleatum to epithelial cells, and inter-
fered with the coaggregation of these two species in a
dose-dependent manner. Locally, in infected subcuta-
neous chambers, NDM reduced TNF-a levels induced
by inoculation of a P. gingivalis and F. nucleatum mixture.
In addition, NDM quenched TNF-a expression by
macrophages stimulated with these two bacteria. These
anti-inflammatory features of NDM explain why NDM
reduced the severity of experimental periodontitis in mice
treated with this agent (50).
Gingipain inhibition by green tea-derived
polyphenols
Traditional Chinese medicine has used tea as a medica-
ment for many illnesses since ancient times. Recent
epidemiological and clinical studies show that consump-
tion of green tea and/or selected tea constituents con-
tributes to a reduction in the riskof cardiovascular disease
and cancer, and may provide oral health benefits. Tea
polyphenols (catechins) are thought to be responsible for
the biological properties of green tea since they exhibit
antioxidant, anti-inflammatory, anti-cancer, and antimi-
crobial activities. In the case of periodontal disease, case-
controlled, randomized, split-mouth clinical studies
showed significant improvement of clinical parameters
(gingival index, probing pocket depth, clinical attachment
loss, and plaque index) in sites treated with green tea
catechins delivered locally, in comparison to sites that
received only a routine treatment of subgingival scaling
and root planning (5155). This improvement of period-
ontal status at sites treated with catechins is due to direct
inhibition of host proteases (56, 57) and suppression
of the release of proinflammatory cytokines and chemo-
kines from oral epithelial cells and fibroblasts (56, 58).
Catechins can also directly inhibit gingipains and this may
contribute to the therapeutic effect of green tea extract.
Catechin derivatives, including epigallocatechin gallate,
the main constituent of green teapolyphenols, epicatechin
gallate, gallocatechin gallate, and catechin gallate, signifi-
cantly inhibited Rgp activity with an IC50 in the range
of 35 mM (59). The potency of catechins to inhibit
gingipains together with their ability to interfere with
P. gingivalis growth and suppress the inflammatory reac-
tion make these compounds perfect candidates for
the development of therapeutics against periodontitis
and potentially associated systemic illnesses, such as
atherosclerosis (60).
Gingipain inhibition by Myrothamnus flabellifolia
extract
A polyphenol-enriched extract from Myrothamnus
flabellifolia (MF) is a more potent inhibitor for Rgp
than Kgp (61). At 50 mg/mL, MF reduced Rgp activity
by 7080% and 100 mg/mL MF reduced Rgp activity by
approximately 80%. By contrast to Rgp, Kgp activity was
only reduced by approximately 50% with 100 mg/mL MF.
MF also had anti-adhesive effects mediated by its
interaction with bacterial outer membrane proteins
(OMPs). However, it exhibits high toxicity, which may
limit its clinical use to multiple low-dose applications.
Gingipain inhibition by antibodies and
vaccines
Antibody-binding epitopes in the vicinity of the sub-
strate-binding cleft of certain proteases can be used to
limit their protease activity. The best examples of this are
the natural antibodies against IgA1 proteases produced
by mucosal pathogens (6265). Although no natural
antibodies with gingipain inhibitory activity are known,
IgYantibodies isolated from the yolks of hens immunized
with purified gingipains exerted dose-dependent inhibi-
tion of gingipain hydrolysis of synthetic substrates. In
addition, the anti-gingipain IgY antibodies strongly
interfered with gingipain-induced human epithelial cell
detachment (66), and were effective immunotherapeutic
agents in the treatment of periodontitis in humans.
A small scale clinical trial revealed that periodontal sites
treated with anti-gingipain IgY in addition to routine
subgingival scaling and root planning, showed signifi-
cantly reduced numbers of P. gingivalis, decreased pocket
probing depth (attachment loss), and attenuated bleeding
on probing (BOP) in comparison to sites treated only
with subgingival scaling and root planning (67).
Vaccinationwithgingipains hasbeenreportedtoyielda
protectiveeffectagainstP.gingivalisinfection(6870).The
vaccines tested were mainly peptide and DNA vaccines.
While DNA vaccines induce both cellular and humoral
immunity, peptide vaccines induce only humoral immu-
nity. In a review on P. gingivalis vaccines, RgpA and Kgp
were proposed as potential vaccines for the prevention of
P. gingivalis-induced periodontitis (71). O’Brien-Simpson
et al. (72) reported that RgpA-Kgp peptide-based immu-
nogens together with incomplete Freund’s adjuvant gave
protection against P. gingivalis in a murine lesion model.
The protease domain of Kgp serves as a hemoglobin-
binding domain and may also constitute an immunogen
for the induction of immunity from P. gingivalis infection
(73). Immunization in a rat periodontitis model with the
RgpA-Kgp protease-adhesion complex protected against
colonizationofthesubgingivalsulcuswithP.gingivalisand
reduced periodontal bone loss by inducing a high titer of
serumIgG2(74).ImmunizationwithRgpAstimulatedthe
production of HA domain-specific antibodies, which
Ingar Olsen and Jan Potempa
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a murine model (69). However, only certain parts of
HA domain-specific antibodies have protective functions
(75); therefore, antibodies produced against the protease
domain may be more promising. Genco et al. (42) found
thatantibodiesdirectedagainsttheamino-terminalregion
of the protease domain of Rgps induced a protective
immune response against P. gingivalis infection in a mouse
chamber model. A study in humans suggested that
inability to produce sufficient antibodies to the protease
domainofgingipainsmaybeanetiologicfactorforchronic
periodontitis and antibodies against the protease domain
are important in the prevention of periodontitis (76).
RgpA contains a proprotein, a protease domain, and a
hemagglutinin-adhesion (HA) domain consisting of con-
secutive hemagglutinin polypeptides of 44 kDa, 15 kD, 17
kDa, and 27 kDa (HGP44, HGP15, HGP17, and HGP27,
respectively).TheHAdomainissimilartothatencodedby
the hemagglutinin A (HagA) gene and the HA domains of
Kgp (77). Of note, recolonization of patients subjected to
periodontal treatment with P. gingivalis was prevented by
local passive immunization with monocolonal antibodies
(78) recognizing heamagglutinating epitope in HGP44
(79). This important observation constitutes a proof of
concept that gingipains constitute perfect target for
vaccine development. Indeed, immunization of mice with
RgpA stimulated production of P. gingivalis- and RgpA-
specific IgG antibodies directed primarily against the HA
domain of this protein (68). O’Brien-Simpson et al. (80)
found that when the RgpA-Kgp complex, functional
binding motif, or active-site peptides thereof were used
as avaccine, a Th2 response was induced that blocked the
function of the RgpA-Kgp complex and protected against
periodontal bone loss in the murine periodontitis model.
Recently, Muramatsu et al. (81) examined the protective
effect of immunization with RgpA domain vaccines and
reported that HGP44 induced protection against P.
gingivalis-induced alveolar bone loss in mice. The
HGP44 domain-coding DNAvaccine was responsible for
this protection. The HPG44-coding region could thus be a
candidate antigen for a DNA vaccine. Previously, anti-
bodiesinducedbytheHPG44domaininhibitedbindingof
the RgpA-Kgp complex to fibrinogen, fibrinonectin, and
collagen type IV (80) and enhanced opsonization and
killing of invasive and non-invasive strains of P. gingivalis
(82). Yonezawa et al. (83) found that immunization by an
RgpA DNA vaccine protected mice against invasive P.
gingivalisinfectionthroughregulationofinterferon-g.The
antibodies produced inhibited several P. gingivalis viru-
lence activities including Rgp-mediated hemagglutination
and binding to collagen. This could be an important
consideration for the immunization of animals against
periodontitis.
Gingipain inhibition by other bacteria
Other bacteria present in dental plaque may modulate the
proteolytic activity of P. gingivalis. Tenorio et al. (84)
found that a number of oral bacterial strains in sub-
gingival plaque were capable of reducing the cytotoxic
effects of P. gingivalis in vitro and interfering with its
growth and proteolytic activity. Further research is
required to determine whether this observation could
lead to new probiotic agents and novel strategies for
treatment of periodontal disease.
Concluding remarks
A number of gingipain inhibitors have been detected.
Broadly speaking they can be classed as NPDs of
gingipains, synthetic inhibitors, inhibitors from natural
sources, antibiotics, antiseptics, antibodies, and bacteria.
A few of the synthetic inhibitors were devised to elucidate
the structures, catalytic mechanisms, and reaction inter-
mediates of gingipains. Although there is no doubt that
several of these inhibitors are highly potent, they are
generally unsuitable for in vivo use because of their
chemical reactivity and/or ability to interfere with activity
of essential host proteases. Many other synthetic com-
poundshavehighorunknowntoxicity.Nevertheless,these
synthetic compounds are effective in preventing P.
gingivalis pathogenicity if bacteria are pre-incubated with
theinhibitorspriortoinoculationofexperimentalanimals.
This represents an interesting strategy to arrest P.
gingivalis-induced periodontal disease. The KYT inhibi-
tors are the most promising synthetic compounds since
they have low toxicity and high selectivity for gingipains.
Taking into account the absolute dependence of P.
gingivalis virulence on gingipain activity it is perplexing
thatnoneofthesyntheticcompoundshavebeendeveloped
and tested in pre-clinical trials. Clearly, more work is
requiredtodevelop synthetic inhibitors andassess them in
clinicaltrials.Inhibitorsfromnaturalsourcesareatamore
advanced stage with several undergoing testing on a
limitedscaleinclinicaltrialsandshowingpromisingthera-
peutic results. Cranberry and rice extracts are especially
interesting not only because they interferewith gingipains,
but also because they prevent growth and biofilm forma-
tion by periodontopathogens. Despite all this research,
prophylactic and therapeutically useful inhibitors to treat
and/or prevent periodontitis still require further develop-
ment. In doing this it is important to differentiate between
inhibition of proteolytic enzyme activity through some
form of active site-directed strategy versus interference
with the hemagglutination/adherence properties of RgpA
and Kgp. It is not clear how effective a strategy it will be
thattargetsonlyasingleorganisminthecomplexdysbiotic
microbiota of periodontal disease. Since additional peri-
odontopathogens such as T. forsythia and T. denticola also
produce proteinases, future research should investigate
their susceptibility to gingipain inhibitors as well.
Strategies for the inhibition of gingipains
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